Approval of Sovaldi triggered active new drug competition

Published: 2015-09-14 14:08:46

Updated: 2015-09-14 14:10:34

‘Sovaldi(sofosbuvir), a hepatitis C treatment, has been approved.

According to the industry concerned on the 11^th, Gilead Sciences Korea’s Sovaldi has acquired approval from Ministry of Food and Drug Safety(MFDS) on the 10^th.

Gilead turned in an application for a new drug last January, and in terms of Harvoni(sofosbuvir, ledipasvir), it is expected to fail in the application this October.

So...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.